热门标签

新2手机网址(www.99cx.vip)_Pressure on Pharmaniaga margins

时间:2个月前   阅读:158   评论:4

新2手机网址www.99cx.vip)实时更新发布最新最快的新2手机网址、新2手机网址线路、新2手机网址登录网址、新2手机网址管理端、新2手机网址手机版登录网址、新2手机皇冠登录网址。

,“The gradual rise in consumer healthcare sales mix in the medium term will likely dilute the overall margins slightly, given the segment’s lower margin owing to its higher advertising and promotion costs,” CGS-CIMB Research said in its latest report.

KUALA LUMPUR: Pharmaniaga Bhd’s profit margins could see some pressures ahead on higher input costs.

The group noted in its recent briefing with analysts that higher input costs may potentially be felt from higher active pharmaceutical ingredient prices and the weaker ringgit to US dollar.

However, it said these factors have had a minimal impact so far on its margins, noting that this could change if the situation continues over the next three months or longer.

“The gradual rise in consumer healthcare sales mix in the medium term will likely dilute the overall margins slightly, given the segment’s lower margin owing to its higher advertising and promotion costs,” CGS-CIMB Research said in its latest report.

The research house has lowered its earnings before interest, taxes, depreciation and amortisation (Ebitda) margins forecast for Pharmaniaga slightly and expects Ebitda margin for the financial year 2022 (FY22) to contract by 3.3 percentage points to 4.6%.

“We believe our cuts sufficiently reflect the potential input cost pressures ahead,” it said.

Due to this, the research house had also cut its forecast core earnings per share for FY22-FY24 by 6% to 7.5% to factor in lower Ebitda margins and higher FY23-FY24 forecast capital expenditures for new warehouses.

CGS-CIMB Research had maintained its “add” rating on the stock but cut its target price to 73 sen, which is based on 15 times forecast price-to-earnings ratio for 2023.

Meanwhile, Pharmaniaga hopes to double or even triple its consumer healthcare revenue contribution by FY24 from a low base or less than 1% of revenue so far.

This would be supported by new product launches, which would help offset a normalisation in Vitamin C demand that was boosted by the Covid-19 surge prior to this.

“It is also exploring possible acquisitions of brands with established product ranges and customer base to expedite the consumer healthcare expansion and it has not factored this into its revenue target,” it added.

Pharmaniaga’s manufacturing plant for oral solid dosages in Bangi, Selangor, is operating at a utilisation rate of about 65%, which gives it room to ramp up output if the need arises.

“We believe the ample excess production capacity at Pharmaniaga’s existing plants will give it space for more output in the next three to five years on rising pharmaceutical demand and new product launches,” CGS-CIMB Research said.

Demand can be met with little to no incremental capital expenditures, it said.

上一篇:飞机群组索引(www.Tg888.vip)

下一篇:足球分析师 --(www.99cx.vip)

网友评论

  • 2022-07-04 00:02:27

    我们这一生是会有无数次错过,有的令人惋惜,有的让人心痛,有的使人庆幸,唯独这一次错过,只有暖暖的感动和满满的欣喜。那么,就在隔着重重岁月,对着当初站在校门口的爱的他,用力地喊一句:“我很幸福,愿你安好!”这个最爱,安利你们

  • 2022-07-19 00:01:40

    我们喜欢的,要么错过了,要么已经名花/草有主了;喜欢我们的,总觉得缺少一种感觉。于是我们报着追求真感情的态度,寻找爱情,可是总觉得交际面太窄,没有办法认识理想的类型;于是我们报着宁缺毋滥的态度,自由着,孤单着。就是很好,没得说